The Asthma Urgency - Shifting the Rescue Paradigm

This webinar addresses the prevalence of asthma and exacerbations in the US, the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic, the genomic & nongenomic mechanisms of action of inhaled asthma therapies, and the latest expert opinion on treatment of asthma to mitigate morbidity.

Price: FREE for members and non-members

Recorded on: November 6, 2024

CME is not offered for this activity.

Supported by AstraZeneca.

Additional Resources

Explore other archived clinical webinars here.

Target Audience

Allergists and allied health professionals working with allergists.

Learning Objectives

After this webinar, participants should be better able to…

  • Discuss the prevalence of asthma and exacerbations in the US
  • Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
  • Identify both the genomic and nongenomic mechanisms of action of inhaled asthma therapies
  • Analyze the latest expert opinion on treatment of asthma to mitigate morbidity
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Course opens: 
11/08/2024
Course expires: 
12/31/2025
Rating: 
0

Gerald B. Lee, MD, FACAAI, is an Associate Professor of Pediatrics and Internal Medicine in the Allergy and Immunology Division at Emory University School of Medicine. He is the Program Director of the Emory allergy/immunology fellowship and a thread director for the Emory immunology preclinical curriculum. He is the Assistant Editor for AllergyWatch, and co-host of the AllergyTalk podcast.

Disclosures:
Novartis: Speaker

William C. Anderson III, MD, FACAAI, is Associate Professor of Pediatrics at Children’s Hospital Colorado and University of Colorado School of Medicine and board-certified in Pediatrics, Internal Medicine, and Allergy and Immunology. At Children’s Hospital Colorado, Dr. Anderson is the director of the Multidisciplinary Asthma Clinic, co-director of the Improving Pediatric to Adult Care Transition Program, and associated program director for their Allergy and Immunology Fellowship. His clinical and scholarly interests include difficult-to-treat and severe asthma, technology in medicine including electronic medication monitoring, and the transition from pediatric to adult care.

Disclosures:
Genentech: Advisor
Regeneron: Advisor
Sanofi: Advisor

Leonard B. Bacharier, MD, FACAAI, is the Janie Robinson and John Moore Lee Chair in Pediatrics at Vanderbilt University Medical Center. He is a Professor of Pediatrics and Allergy/Immunology/Pulmonary Medicine. He is also the Scientific Director of the Center for Clinical and Translational Research at Vanderbilt. Dr. Bacharier's career has focused on clinical research to help understand and improve the care of children with asthma. His clinical/translational research efforts are directed at the pathogenesis of asthma in early life and approaches to asthma management throughout childhood, including multi-center federally funded clinical trials in asthma.

Disclosures:
AstraZeneca: Researcher, Consultant
DBV Technologies: Advisor
GlaxoSmithKline: Consultant
Novartis: Consultant
Regeneron: Consultant, Speaker
Sanofi: Researcher, Consultant, Speaker

Alan P. Baptist, MD, MPH, FACAAI, is a Professor and Division Head of Allergy and Clinical Immunology at Henry Ford Health in Detroit, Michigan and holds a joint appointment at University of Michigan School of Public Health in Ann Arbor, Michigan. He previously served on the NHLBI 2020 Asthma Guidelines Update Committee. His research interests include asthma in older adults, asthma healthcare disparities, and implementation of asthma guidelines. Dr. Baptist has authored or coauthored over 80 peer-reviewed articles that have been published in journals such as the Journal of Allergy and Clinical Immunology and the Annals of Allergy, Asthma, and Immunology.

Disclosures:
AstraZeneca – Advisor, Researcher
Regeneron – Advisor, Researcher
Novartis – Researcher
Sanofi – Advisor
GlaxoSmithKline – Advisor

Non-CME

Please login or create an account to take this course.